The DPMCDA Medications Discovery & Toxicology Branch plans, designs, implements, and coordinates a set of comprehensive pre-clinical discovery programs with the goal of identifying potential medications to treat the most common abused illegal drugs such as cocaine, methamphetamine, marijuana, nicotine, and opiates. Within the discovery programs, the primary activities of the Medications Discovery & Toxicology Branch include in vitro receptor and transporter activity screening; pre-clinical behavioral screening; and pharmacological profiling of candidate medications. The Branch is working to identify new molecular entities and to manage information on drug discovery targets. The Drug Discovery and Development System helps researchers acquire, track, analyze, and manage data throughout a compound's lifecycle. These data are used to identify potential compounds to recommend for advancement to NIDA's drug development pipeline. The Drug Discovery and Development System (Discovery Application) 
The Discovery application gives NIDA the ability to record, monitor and track the progress of a compound and compare the completed laboratory results to other compounds across and within the addiction treatment discovery program. The application generates authorization forms and letter templates that are used by NIDA to send and receive compound information to compound submitters and laboratory testing sites. The Discovery application displays summary and detailed compound testing data conducted by and received from the laboratories. These results aid in the compound advancement decision making process to assess a compound's potential as an alternative substitute or treatment for persons with drug dependency. For more details, contact Discovery Support at NIDA_Discovery@imc.com. |
NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version
|
